Clinical Trial Update: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 pivotal study in HER2-negative locally recurrent or metastatic breast cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Locally Recurrent Breast Cancer

Snippet

Sponsor: Spexis AG | Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2023-11-01